BRIEF—Bial and Eisai highlight effectiveness of Zebinix as monotherapy

Portugal’s Bial and Japan’s Eisai have released a new sub-analysis of data from the Euro-Esli study, showing greater effectiveness of Zebinix (eslicarbazepine acetate) as a monotherapy, compared with as an adjunctive therapy in adults with focal-onset epilepsy.

The firms said that, “whilst this may be expected, given that patients managed on monotherapy will tend to be less refractory to treatment, it provides real-world substantiation for the value of eslicarbazpine acetate as monotherapy in newly diagnosed patients.”

Analysis author Martin Holtkamp said: “These findings complement those found in the Phase III clinical trials, providing further evidence to confirm its effectiveness in a clinical practice setting.”

The firm’s have a long-standing collaboration around Zebinix. The product was approved as a monotherapy to treat epilepsy in Europe last year.